H K Chew

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors
    H K Chew
    Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA
    Ann Oncol 23:1023-9. 2012
  2. ncbi request reprint 25th Chemotherapy Foundation Symposium. Innovative Cancer Therapy for Tomorrow. 6-10 November 2007, New York, NY, USA
    Helen K Chew
    University of California, Davis, Division of Hematology Oncology, 4501 X Street, Sacramento, CA 95817, USA
    IDrugs 11:90-3. 2008
  3. doi request reprint The incidence of venous thromboembolism among patients with primary lung cancer
    H K Chew
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis, Sacramento, CA, USA
    J Thromb Haemost 6:601-8. 2008
  4. ncbi request reprint Incidence of venous thromboembolism and the impact on survival in breast cancer patients
    Helen K Chew
    Division of Hematology Oncology, University of California Davis, CA, USA
    J Clin Oncol 25:70-6. 2007
  5. pmc Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer
    Helen K Chew
    Department of Internal Medicine, Division of Hematology Oncology, University of California Davis, Sacramento, CA 95817, USA
    J Clin Oncol 27:2163-9. 2009
  6. pmc A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338
    Helen K Chew
    Department of Internal Medicine, Division of Hematology Oncology, University of California Davis, Sacramento, CA 95817, USA
    Clin Breast Cancer 8:511-5. 2008
  7. ncbi request reprint Incidence of venous thromboembolism and its effect on survival among patients with common cancers
    Helen K Chew
    Divisionsof Hematology Oncology, Department of Internal Medicine, and Department of Public Health Sciences, University of California, Davis, Sacramento, CA 95817, USA
    Arch Intern Med 166:458-64. 2006
  8. ncbi request reprint Medical management of breast cancer: today and tomorrow
    Helen K Chew
    Breast Cancer Program, Department of Internal Medicine Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, California, USA
    Cancer Biother Radiopharm 17:137-49. 2002
  9. ncbi request reprint Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival
    Allison Alcalay
    Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis, Sacramento, CA 95817, USA
    J Clin Oncol 24:1112-8. 2006
  10. ncbi request reprint High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
    Carol M Richman
    University of California Davis, Sacramento, California 95817, USA
    Clin Cancer Res 11:5920-7. 2005

Research Grants

Detail Information

Publications19

  1. doi request reprint Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors
    H K Chew
    Department of Internal Medicine, University of California Davis, Sacramento, CA 95817, USA
    Ann Oncol 23:1023-9. 2012
    ..Chemotherapy in combination with small-molecule epidermal growth factor receptor inhibitors has yielded inconsistent results. Based on preclinical models, we conducted a phase I trial of two schedules of lapatinib and vinorelbine...
  2. ncbi request reprint 25th Chemotherapy Foundation Symposium. Innovative Cancer Therapy for Tomorrow. 6-10 November 2007, New York, NY, USA
    Helen K Chew
    University of California, Davis, Division of Hematology Oncology, 4501 X Street, Sacramento, CA 95817, USA
    IDrugs 11:90-3. 2008
  3. doi request reprint The incidence of venous thromboembolism among patients with primary lung cancer
    H K Chew
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis, Sacramento, CA, USA
    J Thromb Haemost 6:601-8. 2008
    ..The incidence of venous thromboembolism (VTE) by lung cancer histology and stage is unknown...
  4. ncbi request reprint Incidence of venous thromboembolism and the impact on survival in breast cancer patients
    Helen K Chew
    Division of Hematology Oncology, University of California Davis, CA, USA
    J Clin Oncol 25:70-6. 2007
    ..The incidence of venous thromboembolism (VTE) and the risk factors associated with development of VTE have not been reported in a large population-based study of breast cancer patients...
  5. pmc Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer
    Helen K Chew
    Department of Internal Medicine, Division of Hematology Oncology, University of California Davis, Sacramento, CA 95817, USA
    J Clin Oncol 27:2163-9. 2009
    ..Two parallel, phase II trials were conducted to evaluate the response rate, response duration, and toxicities of the combination. Genetic polymorphisms were analyzed for correlation with outcomes...
  6. pmc A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338
    Helen K Chew
    Department of Internal Medicine, Division of Hematology Oncology, University of California Davis, Sacramento, CA 95817, USA
    Clin Breast Cancer 8:511-5. 2008
    ....
  7. ncbi request reprint Incidence of venous thromboembolism and its effect on survival among patients with common cancers
    Helen K Chew
    Divisionsof Hematology Oncology, Department of Internal Medicine, and Department of Public Health Sciences, University of California, Davis, Sacramento, CA 95817, USA
    Arch Intern Med 166:458-64. 2006
    ..The incidence of venous thromboembolism after diagnosis of specific cancers and the effect of thromboembolism on survival are not well defined...
  8. ncbi request reprint Medical management of breast cancer: today and tomorrow
    Helen K Chew
    Breast Cancer Program, Department of Internal Medicine Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, California, USA
    Cancer Biother Radiopharm 17:137-49. 2002
    ..However, novel targeted therapies are changing the treatment armamentarium and hold great promise. These new directions of treatment will be discussed as well as areas of controversy...
  9. ncbi request reprint Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival
    Allison Alcalay
    Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis, Sacramento, CA 95817, USA
    J Clin Oncol 24:1112-8. 2006
    ..To describe the incidence and outcomes associated with venous thromboembolism (VTE) among patients with colorectal cancer...
  10. ncbi request reprint High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
    Carol M Richman
    University of California Davis, Sacramento, California 95817, USA
    Clin Cancer Res 11:5920-7. 2005
    ..In these phase I studies, paclitaxel was combined with radioimmunotherapy in patients with metastatic hormone-refractory prostate cancer or advanced breast cancer...
  11. pmc Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data
    Donald A Barkauskas
    Graduate Group in Biostatistics with a Designated Emphasis in Biotechnology, School of Medicine, University of California, Davis, CA 95616, USA
    Bioinformatics 25:251-7. 2009
    ..We have developed novel methods for analyzing this type of mass spectrometry data and applied it to eight datasets from three different types of cancer (breast, ovarian and prostate)...
  12. ncbi request reprint Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults
    Richard H White
    Departments of Internal Medicine, Medicine, Medicine and Statistics, and Public Health Sciences, University of California Davis, Sacramento, CA 95817, USA
    Arch Intern Med 165:1782-7. 2005
    ..It is unclear how frequently unprovoked venous thromboembolism (VTE) reflects the presence of an occult cancer...
  13. ncbi request reprint Phase I trial of combination nab-paclitaxel and pemetrexed in advanced solid tumors
    C Ho
    British Columbia Cancer Agency, Vancouver, BC, Canada University of California Davis Campus, Sacramento, CA
    J Clin Oncol 26:13530. 2008
    ..We hypothesized that the combination of ABI-007 and pemetrexed will have at least an additive anti-tumor effect and will be well-tolerated with manageable side effects...
  14. ncbi request reprint Genetic evaluation of cancer: the importance of family history
    H K Chew
    Division of Hematology/Oncology, University of California-Davis Cancer Center, 4501 X St, Ste 3016, Sacramento, CA 95817, USA
    Tex Med 97:40-5. 2001
    ..Risk-reduction strategies and options for high-risk patients as well as legal and ethical issues pertaining to genetic counseling and testing will be considered...
  15. ncbi request reprint A serum glycomics approach to breast cancer biomarkers
    Crystal Kirmiz
    Department of Chemistry, University of California, Davis, California 95616, USA
    Mol Cell Proteomics 6:43-55. 2007
    ..quot;..
  16. doi request reprint The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer
    Rasanamar Sandhu
    Department of Internal Medicine, Division of Hematology Oncology, University of California Davis, Sacramento, California, USA
    Cancer 116:2596-603. 2010
    ..The incidence, risk factors, time course, and impact on survival of venous thromboembolism (VTE) in a large, population-based study of patients with bladder cancer have not been identified previously...
  17. pmc Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival
    Grace H Ku
    Division of Hematology and Oncology, School of Medicine, University of California San Diego, CA, USA
    Blood 113:3911-7. 2009
    ..In the patients with ALL, development of VTE was associated with a 40% increase in the risk of dying within 1 year. The incidence of VTE in acute leukemia is appreciable, and is comparable with the incidence in many solid tumors...
  18. ncbi request reprint Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623
    Halle C F Moore
    Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 25:1677-82. 2007
    ....
  19. ncbi request reprint Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment
    Agnes Juhasz
    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Oncol Rep 15:1299-304. 2006
    ..Furthermore this assay may assess whether WBC samples are an appropriate surrogate tissue for approximating target down-regulation in the tumor...

Research Grants1

  1. Venous thromboembolism among California cancer patients
    Helen Chew; Fiscal Year: 2003
    ..abstract_text> ..